口服抗凝治疗终末期肾病患者房颤:支持立场
本文支持对终末期肾病合并房颤患者使用口服抗凝。华法林获益风险比窄,需筛选卒中高风险且出血风险低的患者;Meta分析显示华法林对卒中(HR 1.12)和死亡率(HR 0.96)无影响但增加大出血(HR 1.30)。新型口服抗凝药关键试验排除了终末期肾病患者,数据有限;阿哌沙班已获指征,可能优于华法林。
要点
- 华法林对终末期肾病合并房颤患者的卒中(HR 1.12)和死亡率(HR 0.96)无显著影响,但增加大出血风险(HR 1.30)。
- 华法林成功使用依赖于筛选卒中高风险且出血风险低的非瓣膜性房颤患者。
- 阿哌沙班已获终末期肾病指征,基于华法林证据及使用难度,可能优于华法林。
核心结论
- 终末期肾病患者应接受长期抗凝治疗,前提是出血风险可接受,阿哌沙班已获指征且可能优于华法林。
研究设计与样本
- 本文为支持立场论述,引用一项关于华法林用于非瓣膜性房颤合并终末期肾病患者的Meta分析及新型口服抗凝药关键试验证据。
主要发现
- Meta分析显示华法林对卒中风险无影响(HR 1.12;95%CI 0.69-1.82;P=0.65),对死亡率无影响(HR 0.96;95%CI 0.81-1.13;P=0.60),但与大出血风险增加相关(HR 1.30;95%CI 1.08-1.56;P<0.01)。
- 关键试验中新型口服抗凝药在非瓣膜性房颤合并轻中度肾功能损害患者中的疗效和安全性至少不劣于华法林。
- 终末期肾病患者的临床数据有限,因为关键试验排除了此类患者。
关键数值与推荐
- 华法林对卒中风险HR 1.12(95%CI 0.69-1.82;P=0.65),对死亡率HR 0.96(95%CI 0.81-1.13;P=0.60),对大出血HR 1.30(95%CI 1.08-1.56;P<0.01)。
- 阿哌沙班目前已在终末期肾病中获指征用于此适应症。
临床怎么用
- 作者认为终末期肾病患者应考虑长期抗凝治疗,前提是出血风险可接受。
- 作者认为阿哌沙班可能优于华法林,因华法林证据体、使用难度及相关不良事件。
局限性
- 终末期肾病患者的临床数据有限,因为关键试验排除了此类患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Warfarin has had a thin margin of benefit over risk for the prevention of stroke and systemic embolism in patients with ESRD because of higher bleeding risks and complications of therapy. The successful use of warfarin has been dependent on the selection of patients with nonvalvular atrial fibrillation at relatively high risk of stroke and systemic embolism and lower risks of bleeding over the course of therapy. Without such selection strategies, broad use of warfarin has not proven to be beneficial to the broad population of patients with ESRD and nonvalvular atrial fibrillation. In a recent meta-analysis of use of warfarin in patients with nonvalvular atrial fibrillation and ESRD, warfarin had no effect on the risks of stroke (hazard ratio, 1.12; 95% confidence interval, 0.69 to 1.82; P=0.65) or mortality (hazard ratio, 0.96; 95% confidence interval, 0.81 to 1.13; P=0.60) but was associated with increased risk of major bleeding (hazard ratio, 1.30; 95% confidence interval, 1.08 to 1.56; P<0.01). In pivotal trials, novel oral anticoagulants were generally at least equal to warfarin for efficacy and safety in nonvalvular atrial fibrillation and mild to moderate renal impairment. Clinical data for ESRD are limited, because pivotal trials excluded such patients. Given the very high risk of stroke and systemic embolism and the early evidence of acceptable safety profiles of novel oral anticoagulants, we think that patients with ESRD should be considered for treatment with chronic anticoagulation provided that there is an acceptable bleeding profile. Apixaban is currently indicated in ESRD for this application and may be preferable to warfarin given the body of evidence for warfarin and its difficulty of use and attendant adverse events.
引用
- McCullough PA, Ball T, Cox KM, et al. Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro. Clin J Am Soc Nephrol. 2016. PMID: 27797888. doi:10.2215/CJN.02680316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。